Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in ...

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. "We'll ...

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

Alphabet-owned Isomorphic Labs says its first AI-designed drug is nearly ready for human trials, targeting diseases like cancer and heart failure. Nucleus_AI 2797 Stories Tuesday July 08, 2025 , 2 ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Expect AI-made prescription drugs to be ready for clinical trials in a couple of years, predicts Google DeepMind CEO 35,048 people played the daily Crossword recently. Can you solve it faster than ...

Prescription drugs designed by AI could be in clinical trials within years, DeepMind's CEO predicted. Demis Hassabis said in an interview he'd be "disappointed" if it took more than a couple of years.

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.

Google Cloud joins with biotech startups to accelerate AI-driven drug discovery and scientific research - SiliconANGLE [the voice of enterprise and emerging tech] search ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis.